
Hermetica Superfood Encyclopedia
Legacy index-continuity record: the score and narrative are provisional and must not be represented as validated or human-approved.
Review flags: AWAITING_SEMANTIC_VALIDATION
Benfotiamine is a fat-soluble derivative of thiamine (vitamin B1) that crosses cell membranes more efficiently than regular thiamine. It activates transketolase enzyme and blocks advanced glycation end product (AGE) formation, particularly benefiting diabetic neuropathy and glucose metabolism.

Reported Benefits (Provisional)
Origin & History

Benfotiamine is a fat-soluble derivative of thiamine (vitamin B1), synthesized for enhanced bioavailability and absorption. It is produced through chemical modification of thiamine, making it more effective in the body.
Research Narrative (Provisional)
RCTs and observational studies have shown benfotiamine's effectiveness in managing diabetic neuropathy and supporting metabolic health. Its superior absorption compared to thiamine is well-documented.
Preparation & Dosage
Dosage guidance is withheld because the publication gate has not recorded adequate support for this profile.
Nutritional Profile
- Provides a bioavailable form of vitamin B1. - Fat-soluble for enhanced absorption. - Free from artificial additives.
Reported Mechanism (Provisional)
Benfotiamine converts to thiamine diphosphate intracellularly, activating transketolase in the pentose phosphate pathway. This activation redirects glucose metabolites away from forming advanced glycation end products (AGEs) and inflammatory compounds. It also enhances the hexose monophosphate shunt, reducing oxidative stress through increased NADPH production.
Clinical Narrative (Provisional)
Multiple randomized controlled trials involving 300-400 participants demonstrate benfotiamine's efficacy for diabetic neuropathy at doses of 300-600mg daily. Studies show 40-50% improvement in neuropathy symptom scores and nerve conduction velocity after 6-12 weeks of treatment. Evidence is strongest for peripheral diabetic neuropathy, with limited but promising research on retinopathy and nephropathy. Most trials are relatively small and short-term, requiring larger long-term studies for definitive conclusions.
Also Known As
Research updates — and 25% off your first order
Join our list for source-aware wellness education, review-state updates, and product news — and unlock 25% off your first Hermetica order. Educational content is not medical advice. No spam, unsubscribe anytime.







